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Impaired Endothelial Nitric Oxide 
Synthase Homodimer Formation 
Triggers Development of Transplant 
Vasculopathy - Insights from a 
Murine Aortic Transplantation 
Model
Rupert Oberhuber1, Gregor Riede1, Benno Cardini1, David Bernhard2, Barbara Messner3, 
Katrin Watschinger4, Christina Steger5, Gerald Brandacher 1,6, Johann Pratschke1,7, 
Georg Golderer4, Ernst R.  Werner4 & Manuel Maglione1
Transplant vasculopathy (TV) represents a major obstacle to long-term graft survival and correlates 
with severity of ischemia reperfusion injury (IRI). Donor administration of the nitric oxide synthases 
(NOS) co-factor tetrahydrobiopterin has been shown to prevent IRI. Herein, we analysed whether 
tetrahydrobiopterin is also involved in TV development. Using a fully allogeneic mismatched (BALB/c 
to C57BL/6) murine aortic transplantation model grafts subjected to long cold ischemia time developed 
severe TV with intimal hyperplasia (α-smooth muscle actin positive cells in the neointima) and 
endothelial activation (increased P-selectin expression). Donor pretreatment with tetrahydrobiopterin 
significantly minimised these changes resulting in only marginal TV development. Severe TV observed 
in the non-treated group was associated with increased protein oxidation and increased occurrence of 
endothelial NOS monomers in the aortic grafts already during graft procurement. Tetrahydrobiopterin 
supplementation of the donor prevented all these early oxidative changes in the graft. Non-treated 
allogeneic grafts without cold ischemia time and syngeneic grafts did not develop any TV. We identified 
early protein oxidation and impaired endothelial NOS homodimer formation as plausible mechanistic 
explanation for the crucial role of IRI in triggering TV in transplanted aortic grafts. Therefore, targeting 
endothelial NOS in the donor represents a promising strategy to minimise TV.
Solid organ transplantation has become the treatment of choice for patients with end stage organ failure. However, 
excellent short-term graft survival does currently not mirror long-term outcome, as transplant vasculopathy (TV) 
continues to be its primary obstacle1–3. TV is a multifactorial process. Both, alloimmune and non-alloimmune 
factors influence occurrence and severity of TV, which finally leads to vascular intimal hyperplastic lesions, the 
so-called neointima. Exact pathomechanisms are still unknown, effective prevention is not available4. Important 
non-alloimmune factors are donor age, hypertension, hyperlipidemia and pre-existing diabetes, and drug-related 
side effects (e.g. cytomegalovirus infection, nephrotoxicity and new-onset diabetes after transplantation)3,5, 
1Centre of Operative Medicine, Department of Visceral, Transplant and Thoracic Surgery, Medical University 
Innsbruck, Innsbruck, Austria. 2Cardiac Surgery Research Laboratory, University Clinic for Cardiac Surgery, Medical 
University Innsbruck, Innsbruck, Austria. 3Cardiac Surgery Research Laboratory, Department of Surgery, Vienna 
Medical University, Austria. 4Division of Biological Chemistry, Biocenter, Medical University Innsbruck, Innsbruck, 
Austria. 5Institute of Pathology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria. 6Department of Plastic 
and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins 
University School of Medicine, Baltimore, Maryland, USA. 7Department of General-, Visceral- and Transplantation 
Surgery, Charité, Campus Virchow Klinikum, Berlin, Germany. Correspondence and requests for materials should be 
addressed to E.R.W. (email: ernst.r.werner@i-med.ac.at) or M.M. (email: manuel.maglione@i-med.ac.at)
Received: 19 May 2016
Accepted: 04 November 2016
Published: 24 November 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:37917 | DOI: 10.1038/srep37917
however, there is some evidence that TV severity is predetermined by the degree of ischemia reperfusion injury 
(IRI) of the graft occurring in the process of transplantation3,6,7. IRI results in loss of endothelial cell integrity with 
upregulated expression of proinflammatory cytokines and adhesion molecules8,9. As a consequence, immune cells 
start invading the graft perpetuating a constant inflammatory process resulting ultimately in transplant vasculop-
athy featuring neointimal smooth muscle cell expansion, formation of extracellular matrix and intimal fibrosis10.
Ischemia and, paradoxically, the resumption of blood flow during graft reperfusion cause a dramatic increase 
of superoxide (O2−·) and peroxynitrite (ONOO−) in endothelial cells11,12. This initial oxidative burst has been 
shown to deplete endogenous antioxidants like tetrahydrobiopterin (BH4)13–15. BH4 is also an essential co-factor 
of the nitric oxide synthases (NOS) with profound impact on the structure of all three NOS isoforms, stabilising 
their active homodimeric form and increasing their substrate affinity16,17. With the depletion of intracellular 
BH4 by oxidative stress NOS start producing reactive oxygen species rather than nitric oxide, the so-called NOS 
uncoupling15,17–19. This finally leads to ONOO− formation and ends into a vicious cycle of excessive oxygen radical 
formation, antioxidant consumption and tissue destruction17,20–22.
Recently, we observed in a syngeneic setting, using murine pancreas transplantation model, that BH4 pretreat-
ment of the donor immediately before organ procurement prevented lethal IRI18,23. Since IRI has been observed to 
be an essential trigger of TV development, we wanted to investigate whether and how the same BH4 pretreatment 
protocol of the donor would exert beneficial effects on development of TV. Even though ideal for IRI analyses, 
the previously used pancreas transplantation model is not suited for long-term observations due to progressive 
fibrosis of the parenchyma24. Therefore, in this study we used a fully allogeneic mismatched aortic transplantation 
model. This mouse model, with the aortic interpositioning graft transplanted into the common carotid artery of 
the recipient animal, is a well established mouse model with TV occurring 4 weeks following transplantation25,26.
Results
Neointima formation is minimised by BH4 supplementation. Four weeks following transplantation 
we observed prominent neointima formation in non-treated allogeneic grafts subjected to 24 h cold ischemia 
time (CIT) (group I, n = 10) Fig. 1a,b). In contrast, BH4 pretreatment (group II, n = 9) resulted in significantly 
less intima thickness and intima:media ratio compared to the non-treated allogeneic group (p = 0.008, p = 0.001, 
respectively; Fig. 1c,d,i,j). Of note, allogeneic grafts without CIT (group III, n = 9) and the syngeneic controls 
(group IV, n = 5) had also significantly less intima thickness and intima:media ratio compared to the non-treated 
allogeneic group (group I vs group III: p = 0.0004, p = 0.0006, respectively; group I vs group IV: p = 0.0002, 
p = 0.019, respectively; Fig. 1e–j). Findings were, however, comparable with the BH4 treated group (p = ns; 
Fig. 1a,b,e–j).
Expression of P-selectin is prevented by BH4 supplementation. Endothelial cell activation is char-
acterised by expression of endothelial P-selectin, a hallmark in TV development27,28. Semiquantitive analyses of 
immunohistochemical staining showed significantly increased expression of P-selectin 4 weeks after transplan-
tation in non-treated allogeneic grafts with prolonged CIT (group I, n = 5) compared to allogeneic grafts without 
CIT (group III, n = 5) as well as compared to BH4 treated grafts (group II, n = 5; p = 0.01 and p = 0.01), respec-
tively; Fig. 2a–d). Using immunofluorescence double staining with the endothelial cell marker von Willebrand 
Factor (vWF), P-selectin expression was co-localised in these cells (Fig. 2e). Again, significant differences of 
P-selectin expression between the experimental groups could be seen with the immunofluorescence double stain-
ing (see Supplementary Fig. S1).
Expression of α-smooth muscle actin is prevented by BH4 pretreatment. Another hallmark of 
TV is the accumulation of α -smooth muscle actin (α -SMA) positive cells within hyperplastic intimal lesions29. 
Similarly to endothelial P-selectin expression, we observed high expression of α –SMA in non-treated allogeneic 
grafts with CIT (group I, n = 10). Again, not only allogeneic grafts without CIT (group III, n = 9), but also BH4 
treated allogeneic grafts (group II, n = 9) showed significantly less α -SMA positive cells (p = 0.01 and p = 0.04, 
respectively; Fig. 3).
Infiltration of CD4, CD8 and CD68 positive cells is not influenced by BH4 supplementation. 
CD4 and CD8 positive inflammatory cells as well as CD68 positive macrophages are crucial players in TV devel-
opment30,31. All allogeneic groups (group I, n = 10, group II, n = 9, and group III, n = 9) showed inflammatory 
cell infiltration of CD4, CD8 and CD68 positive cells 4 weeks after transplantation, whereas only in the syngeneic 
controls (group IV, n = 5) no infiltration was detected (Fig. 4).
Protein oxidation and endothelial Nitric Oxide Synthase (eNOS) monomerisation is prevented 
by BH4 supplementation. BH4 is known to be essential for stabilising the active, NO producing, dimeric 
form of eNOS16. In contrast, in its monomeric form eNOS generates radical oxygen species promoting oxidative 
stress32. We therefore assessed protein oxidation status and the amount of eNOS monomers. Oxyblot® analysis 
revealed that already at the time of graft recovery, aortic grafts from non-treated animals showed significantly 
higher protein oxidation compared to grafts from BH4-treated donor animals (n = 5/group; p = 0.003; Fig. 5a). 
After 24 h CIT differences in protein oxidation were still significant (n =  = 5/group; p = 0.02; Fig. 5a), whereas 
after additional 45 min of warm ischemia time (WIT) observed differences in protein oxidation did not reach 
statistical significance anymore (n = 5/group; p = ns; Fig. 5a).
In parallel to the significantly increased protein oxidation, a significantly lower eNOS dimer to monomer ratio 
was measured at the time of graft recovery in grafts from non-treated donors compared to the BH4 treated group 
(n = 5/group; p = 0.01; Fig. 5b). Following 24 h CIT as well as following 24 h and 45 min WIT no significant dif-
ferences were observed (n = 5/group for each time point; p = ns). This is best visible by the amount of monomer 
which is much lower in BH4 treated aortas. A representative Western Blot is shown in Fig. 5c.
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Biopterin concentrations within aortic tissue are increased following donor BH4 supplemen-
tation. The relationship between active tetrahydro-compound BH4 and non-active dihydro-compound, i.e. 
the BH4-to-BH2 (dihydrobiopterin) ratio, rather than absolute concentrations of BH4, has been shown to be 
accountable for normal eNOS function33. Measurements of biopterin concentrations revealed significantly higher 
concentrations of the active tetrahydro-compound in the aorta of treated animals compared to non-treated ani-
mals, as mirrored by significantly higher BH4-to-total biopterin ratios at the time of graft recovery as well as 10 h 
following graft reperfusion (n = 5/group for each time point; p = 0.03 for both time points; Fig. 5d).
Figure 1. Neointima formation. Aortic grafts were taken from tetrahydrobiopterin (BH4) - treated or non-
treated donors, subjected or not subjected to 24 h CIT, and reperfused for 4 weeks. H&E and Elastica van Gieson 
staining: (a+ b) allogeneic non-treated with CIT (group I, n = 10), (c+ d) allogeneic BH4 – treated with CIT 
(group II, n = 9), (e+ f) allogeneic non-treated without CIT (group III, n = 9), (g+ h) syngeneic control group 
with CIT (group IV, n = 5). Closed bars in (a–d) indicate the neointima. Black-staining in (b,d,f,h) indicates 
elastic fibers of the vessel wall. Bar graphs showing (i) intima thickness (μ m) and (j) the intima:media ratio. 
Results are expressed as mean ± SEM. ns = not significant.
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Discussion
This work confirms our hypothesis that a single BH4 supplementation to the donor immediately before organ 
procurement prevents TV in a fully mismatched, murine allogeneic aorta transplantation model. Additional 
major findings of this study are (1) the observation that in non-treated allogeneic aortic grafts prolonged CIT 
is crucial for occurrence of severe TV, and (2) the identification of two non-alloimmune key events happen-
ing already during organ procurement, and which seem to trigger severe TV development: BH4 depletion and 
increased occurrence of inactive eNOS monomers in the graft.
Our results fit very well with the clinical observation that the degree of IRI drastically influences TV devel-
opment, and are in line with the injury hypothesis where nonantigen-dependent pathways play a pivotal role 
in graft deterioration2,3,6,34. These data confirm our hypothesis that there exists a crucial initial event triggering 
alloatherogenesis. Living kidney transplantation represents an ideal example for the importance of IRI. Despite 
Figure 2. Adhesion-molecule expression. Aortic grafts were taken from tetrahydrobiopterin (BH4) - treated 
or non-treated donors, subjected or not subjected to 24 h CIT, and reperfused for 4 weeks: (a) allogeneic non-
treated with CIT (group I, n = 5), (b) allogeneic BH4 – treated with CIT (group II, n = 5), (c) allogeneic non-
treated without CIT (group III, n = 5). Sections were stained for P-selectin (brown; black arrow in (a) indicating 
its luminal expression) and for haematoxylin (nuclei, blue). (d) Bar graph showing the semiquantitative score 
of P-selectin expression. (e) Representative photographs of double immunofluorescence against vWF (red) and 
P-selectin (green) showing the endothelial origin of P-selectin expression in grafts subjected to prolonged CIT. 
Bright field pictures show the vessel wall structure allowing morphological correlation with the staining. Images 
of antibody validation for double immunofluorescence staining can be found as Supplementary Fig. S2. Results 
are expressed as mean ± SEM. ns = not significant.
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similar alloimmune prerequisites graft survival is significantly better in living kidney compared to cadaveric 
kidney recipients35,36. One critical difference between these two transplantation strategies is the extremely short 
cold ischemia time. Also the degree of IRI-associated early microcirculatory disruption in kidney grafts has been 
shown to be predictive for occurrence of TV and interstitial fibrosis/tubular atrophy (IF/TA)37. Similarly, in liver 
transplantation IRI is a major source of long-term morbidity and mortality, significantly influencing the develop-
ment of microangiopathic ischemia type biliary lesions occurring months or even years after transplantation38. 
Recently, a linear correlation between duration of CIT and the extent of TV has also been shown in a rat cardiac 
transplant model39. Taken together, severity of IRI crucially determines further graft development. However, 
there is ongoing controversy whether prolonged CIT per se induces neointima formation (also in a syngeneic 
setting) or whether the allogeneic response is mandatory for neointima formation, and which are the triggering 
events initiating TV development40–42.
In a murine pancreas transplantation model we showed in a syngeneic setting that long CIT leads to lethal 
graft injury in the recipients. This could only be prevented by BH4 pretreatment of the donor. However, due to 
the high amount of active proteases in the pancreas a further dissection of the underlying mechanism was not 
possible18. In the current study, we analysed in an aortic transplantation model the influence of CIT on TV devel-
opment. The novelty consists on the one hand in the better suited model for analysing the hypothesised protective 
effect of BH4 in the early stages of the organ transplantation process, and on the other hand, in the allogeneic 
setting, allowing to analyse the impact of BH4 treatment in the presence of the alloimmune response.
Aortic interpositioning models represent together with heterotopic heart transplantation models accepted 
mouse models for studying TV43. Despite the advantage of transplanting a vascularised organ, heart transplan-
tation models have several drawbacks compared to aortic transplantation models: (i) the heterogeneity of TV 
in the transplanted heart that results in the need for larger numbers of grafts per group44, (ii) the necessity of 
immunosuppressive treatment of the recipient animals that may modify TV dynamics and (iii) also the likelihood 
of chronic ischemia in models using the carotid artery due to the inadequacy of the arterial pressure to enable 
normal coronary perfusion45. In contrast, a major drawback described in the aortic interpositioning model is 
the replacement of donor endothelial and smooth muscle cells by host cells after several weeks following severe 
rejection46. Acting on the assumption that in this study key events happen already during organ procurement we 
opted for the aortic interpositioning model because of the above mentioned advantages. Results achieved in this 
study have to be interpreted on the basis of the used aortic interpositioning model.
Four weeks post transplantation we observed dramatically lower P-selectin expression and lower α -SMA 
expression within neointimal lesions in the allogeneic, treated group compared to the allogeneic, non-treated 
group. P-selectin and α –SMA are two hallmarks of TV. Vascular wall remodelling in TV is characterized by accu-
mulation of α –SMA positive cells within the intima instead of the medial muscle layer, where, as a consequence 
of medial degradation, α –SMA positive cells are replaced by scar tissue10. In addition, P-selectin is known to 
promote smooth muscle cell (SMC) migration into the vascular wall, thereby, supporting neointima formation47.
Interestingly, in contrast to these two endothelial cell activation and TV markers, BH4 pretreatment of 
the donor did not influence the infiltration of CD4 and CD8 positive inflammatory cells as well as of CD68 
positive macrophages, all cells described to be involved in TV30,31. This points to the importance of early 
nonantigen-dependent events on top of antigen-dependent reactions for the development of TV. In fact, neither 
CIT alone, as shown in the syngeneic control group, nor the mere alloimmune cell infiltration observed in the 
allogeneic grafts without CIT triggered severe TV. Hence, IRI seems to be as mandatory as the alloimmune reac-
tion for TV occurrence initiating probably a vascular damage as triggering event, which is then sustained by the 
allogeneic response on top. However, we cannot exclude development of TV in an allogeneic setting without CIT 
Figure 3. α-SMA positive neointimal formation. Aortic grafts were taken from tetrahydrobiopterin (BH4) - 
treated or non-treated donors, subjected or not subjected to 24 h CIT, and reperfused for 4 weeks: (a) allogeneic 
non-treated with CIT (group I, n = 10), (b) allogeneic BH4 – treated with CIT (group II, n = 9), (c) allogeneic 
non-treated without CIT (group III, n = 9). Sections were stained for α -SMA (brown; black arrows in  
(a,b) indicating its expression in the neointima) and for haematoxylin (nuclei, blue). (d) Bar graph showing the 
semiquantitative score of α -SMA expression. Results are expressed as mean ± SEM. ns = not significant.
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later on after the selected endpoint of 4 weeks used in this study. In this regard, it has been shown that late after 
transplantation alloimmune factors gain more importance for TV development3,48.
The observation that BH4 treatment of the donor prevents TV development 4 weeks following transplantation 
supports the hypothesis that the trigger event takes place on a very early stage of the transplant procedure6,34.
BH4 is a powerful naturally occurring antioxidative agent and an essential co-factor of the NOS. BH4 avail-
ability is crucial for formation and stabilisation of active NOS homodimers. Decreased BH4 levels have been 
associated with increased occurrence of inactive eNOS monomers, consistent with NOS uncoupling32. This refers 
Figure 4. Infiltration with inflammatory cells. Aortic grafts were taken from tetrahydrobiopterin (BH4) - 
treated or non-treated donors, subjected to 24 h CIT, and reperfused for 4 weeks: (a,e,i) Allogeneic non-treated 
with CIT (group I, n = 10), (b,f,j) allogeneic BH4 – treated with CIT (group II, n = 9), (c,g,k) allogeneic non-
treated without CIT (group III, n = 9), (d,h,l) syngeneic control group with CIT (group IV, n = 5). Sections were 
stained for CD68 (a–d), CD4 (e–h) and CD8 (i–l) (brown; black arrows in the allogeneic groups indicating 
stained inflammatory cells) and for methylene green (a–d; nuclei, green) and for haematoxylin (e–l; nuclei, 
blue). Representative images of antibody validation for immunohistochemical staining can be found as 
Supplementary Fig. S3. (m,n,o) Bar graphs showing the quantitative analysis of inflammatory cell infiltration. 
Results are expressed as mean ± SEM. ns = not significant.
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Figure 5. Protein oxidation, eNOS monomer formation and biopterin levels. Aortic grafts were taken from 
tetrahydrobiopterin (BH4) - treated or non-treated donors, at different time points (at the time of graft procurement 
≙ “recovery”, following 24 h CIT ≙ “CIT”, following 24 h CIT plus 45 min WIT ≙ “WIT”, and following 24 h CIT 
plus 45 min WIT and 10 h of graft reperfusion ≙ “10 h rep”) and assessed for protein oxidation, eNOS dimerisation 
as well as biopterin content. (a) Bar graph showing the ratio between densitometric values of the Oxyblot® bands 
and those stained with Ponceau red in order to quantify the level of protein oxidation at distinct time points (n = 5/
group for each time point). Representative images of protein oxidation and Ponceau red staining blots can be found 
as Supplementary Fig. S4. (b) Quantification of eNOS dimers and monomers in aortas at distinct time points (n = 5/
group for each time point). (c) Representative blot for determination of eNOS dimers and monomers by western 
blot at distinct time points in native (non-boiled) aortas. Boiled and native (non-boiled) mouse heart tissue samples 
served as controls. D = dimer, M = monomer. (d) Bar graph showing BH4-to-total biopterin ratios in aortas at 
distinct time points (n = 5/group for each time point). Results are expressed as mean ± SEM. ns = not significant.
www.nature.com/scientificreports/
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to the generation of superoxide rather than nitric oxide (NO) by the NOS enzyme due to the electron transfer 
being uncoupled during the enzymatic reaction. NOS uncoupling results in endothelial dysfunction49, a patho-
mechanism which is linked to numerous cardiovascular diseases and is also involved in IRI following solid organ 
transplantation17,50–52. Previous studies showed that prevention of IRI by BH4 is specific for this compound and 
related to its NOS co-factor activity rather than to its antioxidant capacity23,52.
Analyses of intragraft protein oxidation and BH4 levels clearly show a high degree of deleterious oxidative 
damage and BH4 depletion at the time of graft recovery. Both, however, are significantly attenuated by BH4 treat-
ment of donor. Interestingly, this happens even though BH4 is applied only 2 minutes before organ procurement. 
The depletion of BH4 is likely to result from direct oxidative degradation as a consequence of the oxidative stress 
during graft procurement. In fact, under an altered redox state, BH4 availability is impaired as BH4 biosynthesis 
is crucially dependent from a normal cellular redox state16.
In parallel, at the time of graft recovery, retrieved aortic grafts of non-treated donors had a higher amount 
of inactive eNOS monomers compared to grafts from treated animals, in which active eNOS dimers were pre-
dominant. This suggests that intragraft depletion of BH4 which is demonstrated by a reduced BH4-to-BH2 ratio 
within aortic grafts results in increased occurrence of inactive eNOS monomers, a mechanism known to be at the 
basis of endothelial dysfunction17,32,53. In fact, a reduced BH4-to-BH2 ratio, rather than absolute concentrations 
of BH4, is accountable for normal eNOS function33. So, single administration of BH4 to the donor prevented 
decreased BH4-to-BH2 and as a consequence eNOS dysfunction, which in our opinion is of crucial importance 
for TV occurrence. These results are also in line with the disappointing results of oral BH4 treatment in patients 
suffering from coronary artery disease. Despite elevated BH4 levels BH4-to BH2 ratio did not increase. Therefore, 
no effects were seen on endothelial function, vascular superoxide production and eNOS coupling54.
The proposed pathomechanism based on BH4 depletion and increased occurrence of inactive eNOS mon-
omers is also in line with the knowledge that NO inhibits the expression of adhesion molecules55, and with the 
observation that in a balloon angioplasty model with prominent endothelial injury increased generation of NO 
prevented intimal thickening and restenosis of the vessel by inhibiting SMC proliferation56,57. BH4 and NO home-
ostasis have also been shown to play a crucial role in Cyclosporine A (CyA) induced vasomotor dysfunction 
proposing this pathway as a potential therapeutic strategy to prevent CyA induced vascular injury in transplant 
recipients58. However, the crucial difference between our study and the previously published models is the alloim-
mune response. Here, prevention of the non-alloimmune, early oxidative endothelial injury in the graft prevented 
also the development of alloimmune, chronic rejection. So, destabilisation of the active eNOS homodimer, con-
sistent with endothelial dysfunction, appears to be crucial for triggering TV development.
Pretreatment of the donor before organ procurement is not new to the organ transplantation field. Recently, 
therapeutic hypothermia of the donor has been proposed as a promising strategy to protect recipients from 
delayed graft function following kidney transplantation59. Hence, from a clinical point of view, pretreatment of the 
donor with BH4 would be definitely feasible, and application of BH4 minutes before starting organ procurement 
would even ease logistical requirements. In our previous work comparing different BH4 administration strate-
gies like supplementation of the perfusion/storage solution, recipient or donor treatment, only donor treatment 
showed significant protection from IRI18. This is in line with the current results showing crucial events occurring 
already during organ procurement (treatment of the recipient “misses the target”) and also with observation that 
the equilibrative nucleoside transporter ENT1, which is responsible for BH4 uptake, is temperature-dependent. 
The lower the temperature the lower the intracellular BH4 uptake (currently, organs are perfused and stored 
under hypothermic conditions)60,61. Donor pretreatment seems, therefore, to be currently the only option to 
prevent IRI and, as a consequence, TV by BH4. Whether the emergence of normothermic perfusion strategies62 
offers new treatment opportunities for BH4 has to be further analysed.
In conclusion, we observed a direct correlation between increased eNOS monomer amounts due to BH4 
depletion at the time of graft procurement and severe TV development later on. This represents a plausible mech-
anistic explanation of the clinical observation, that severity of IRI crucially influences TV occurrence and graft 
deterioration. These results open new therapeutic scenarios in the prevention of TV, currently a major challenge 
in solid organ transplantation. Pretreatment of the donor with exogenous BH4 or other agents targeting eNOS in 
the graft might represent in this regard a promising future strategy.
Methods
Murine Aortic Transplantation. Ten- to twelve week old male BALB/c (H2d) and C57Bl/6 (H2b) mice 
(Charles River Sulzfeld, Germany) served as size–matched donor-recipient pairs in a fully MHC mismatched 
model, except for one group where C57Bl/6 (H2b) mice served as, both, donors and recipients. Thoracic aortic 
transplantation was performed using a cuff technique as previously described25 under clean, but not sterile con-
ditions, using an operating microscope with 7–70x magnification (SZ-STU2, Olympus Inc. Japan). Animals were 
anesthetised with an intramuscular (i.m.) injection of xylazine (5 mg/kg b.w.) and ketamine (100 mg/kg b.w.). 
In order to prevent postoperative pain, buprenorphin (0.1 mg/kg b.w.) was administered every 12 hours s.c. for 
the first 5 days and carprofen (Rimadyl® ) 4 mg/kg b.w. every 12 hours s.c. for the first week. Break-off criteria 
included a weight loss of more than 10–15% compared to weight at surgery date, apathy, crippling or a very bent 
back. If animals met one of these criteria they were sacrificed using terminal isoflurane inhalation before reach-
ing the clinical end point. The perfusion solution Custodiol (HTK, Dr. Franz Köhler Chemie GmbH, Alsbach–
Hähnlein, Germany) was used. Animals were housed in a barrier pathogen free facility and received human care 
in compliance with the “Principals of Laboratory Animal Care” formulated by the National Society for Medical 
Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of 
Sciences and published by the National Institutes of Health (NIH Publication no. 86–23, revised 1985). All meth-
ods and specimen acquisition performed as well as the care of the animals used were in accordance with accepted 
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guidelines for animal research. Experiments were approved by the Austrian Ministry of Education, Science, and 
Culture (BMWF-66011_0063-II_10b_2010).
Experimental Design. Aortic grafts were subjected to 24 h of preservation on ice CIT, if not otherwise 
specified, and to 45 min “rewarming” in the implantation site before reperfusion (WIT). Occurrence of TV was 
evaluated by histopathology, immunohistochemistry and immunofluorescence 4 weeks following transplanta-
tion, a sufficient time span for neointima development25,26. Study groups consisted of non-treated allogeneic 
donors (group I; n = 10), BH4 treated allogeneic donors (group II; n = 9), non-treated allogeneic donors without 
CIT (group III; n = 9), non-treated syngeneic donors (group IV; n = 5). Treatment consisted of 50 mg/kg b.w. BH4 
((6 R)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride; Schircks Laboratories, Jona, Switzerland), dissolved in 
sterile infusion-grade phosphate buffered saline (PBS) and administered to the donor i.m. 2 min before graft 
recovery18.
In a separate approach, BH4 tissue levels from treated and non-treated donors were measured in aortic grafts 
at the time of graft procurement, following 24 h CIT plus 45 min WIT, and following 10 h of graft reperfusion 
(n = 5 per group). Similarly, Oxyblot® analysis and measurement of eNOS dimerisation were conducted in aortic 
grafts immediately after graft recovery, following 24 h CIT, and in aortic grafts subjected to 24 h of CIT plus 
45 min WIT (n = 5 per group).
Histopathology. Grafts were embedded in liver tissue from the recipient mouse to improve tissue pro-
cessing. Specimens were fixed in 4% buffered formaldehyde and embedded in paraffin. Separated sections were 
stained with haematoxylin & eosin (H&E) or Elastica van Gieson. All vessel sections were digitally photographed 
at 10-fold magnification using a digital camera (Canon Power Shot G5, Canon, Berlin Germany). Captured 
images were divided into 4 quadrants, and in each quadrant 4 measurements of intima and media thickness were 
performed. 3 cross sections per animal were assessed, resulting in 48 measurements per animal. Analyses were 
carried out using Image J 1.32j-software for Java (National Institutes of Health, USA).
Immunohistochemistry. The following primary antibodies were used on paraffin-embedded sections: anti 
α -SMA (Clone 1A4, Code M0851, dilution 1:100, Dakocytomation, Glostrup, Denmark), anti-CD62P (P-selectin, 
NCL-CD62P-367, dilution 1:50, Novocastra Laboratories Ltd, Newcastle upon Tyne, United Kingdom), 
anti-CD68 (Clone PG-M1, code M0876, dilution 1:100, Dakocytomation, Glostrup Denmark), anti-CD8 (Clone 
CD8/144B, code M7103, dilution 1:50, Dakocytomation, Glostrup, Denmark) and anti-CD4 (NCL-L-CD4–1F6, 
dilution 1:100, Novocastra Laboratories Ltd, Newcastle upon Tyne, United Kingdom). To avoid unspecific bind-
ing slides were pre-incubated with the Rodent Block of the Mouse on Mouse Polymer Kit (Abcam, Cambridge, 
United Kingdom). The Vectastain Elite ABC Kit Universal (Vector Laboratories, Burlingame, Ca, USA) was 
applied according to the instructions. The activity of endogenous peroxidase was blocked with 3% hydrogen 
peroxide (H2O2) in methanol. The sections were visualised with the Vector DAB Substrate Kit for Peroxidase (SK-
4100; Vector Laboratories Inc., Burlingame, California, USA) and counterstained with haematoxylin. P-selectin 
as well as α -SMA were assessed based on a previously established four-graded classification63,64. A blinded scien-
tist performed semiquantitative analysis of cell infiltration in 5 non-overlapping high power fields (HPF).
Double Immunofluorescence Staining. Following fixation in 4% paraformaldehyde, dehydration, and 
embedding in paraffin, cross sections were prepared. After deparaffinisation with xylol, heat-mediated antigen 
retrieval in Tris/Ethylenediaminetetraacetic Acid (EDTA) buffer (pH = 9) was performed. Unspecific binding sites 
were blocked using 1% Bovine Serum Albumin (BSA) in Tris-Buffered Saline and Tween (TBS-T). Afterwards, the 
slides were incubated with the primary anti-P-selectin antibody (M-20, Santa Cruz Biotechnology, Heidelberg, 
Germany, dilution 1:50) and the anti- vWF, Dakocytomation, Glostrup, Denmark, dilution 1:400). Next, slides 
were washed with TBS-T and incubated with the secondary antibodies: Alexa-488 for the P-selectin-antibody 
(1:1000, Life Technologies, Vienna, Austria) and Alexa-546 for the vWF-antibody (1:1000, Life Technologies, 
Vienna, Austria). After three washing steps, tissues were mounted in Pro Long Antifade Gold (Life Technologies, 
Vienna, Austria) and image acquisition was conducted using a LSM 510 Meta attached to an Axioplan 2 imaging 
MOT using ZEN software 2008 (Zeiss, Germany). Aortic sections of ApoE -/- fed at high fat diet (for 12 weeks) 
were used as positive controls, as the development of atherosclerotic lesions in this well established mouse model 
is accompanied by the endothelium - specific up-regulation of P-selectin64.
Oxyblot® - Analysis. Oxidative modification of proteins was analysed using the Oxyblot® technology 
(Merck Millipore, Vienna, Austria), which is based on the detection of carbonyl groups introduced into proteins 
by oxidation reactions. Briefly, after mechanical breakup of vascular tissue, preparation of proteins in lysis buffer 
and ultrasound treatment, the non-soluble fraction in the extract was removed. The supernatant was then used 
for derivatisation of carbonyl groups in the protein side chains to 2,4-dinitrophenylhydrazone (DNP-hydrazone) 
by reaction with 2,4-dinitrophenylhydrazine (DNPH). The DNP-derivatised protein samples were then separated 
by polyacrylamide gel electrophoresis (PAGE) followed by blotting onto a nitrocellulose membrane. Thereafter, 
membranes were incubated with primary antibody, specific to the DNP moiety of the proteins (rabbit anti-DNP 
antibody), and then followed by incubation with a horseradish peroxidase-antibody conjugate (secondary 
antibody: goat anti-rabbit horseradish peroxidase (HRP) antibody). The membranes were then treated with 
Enhanced chemiluminescence (ECL, Thermo Fisher Scientific, Vienna, Austria), followed by the detection of the 
signal by exposure to x-ray films. Following development and fixation of films, bands were imaged, and quantified 
using a standard imaging system and normalised to the total protein amount of the respective lane stained with a 
0.1% (w/v) Ponceau S solution with 5% Acetic acid (Sigma Aldrich, Vienna, Austria).
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:37917 | DOI: 10.1038/srep37917
Analysis of eNOS monomer dimer ratio by low temperature PAGE and Western blot. Aortae 
were homogenised with an Ultra Turrax (IKA, Staufen, Germany) in 100 μ l 50 mM TrisHCl, pH 7.4, containing 
150 mM NaCl, 0.5% Triton X-100 and a protease inhibitor mix (GE Healthcare, Vienna, Austria), centrifuged 
at 16000 × g and 4 °C, and protein determined by the Bradford assay (Biorad, Vienna, Austria). Homogenates 
were mixed with standard Laemmli sample buffer at 4 °C with the standard heating step omitted to preserve the 
dimer. To calibrate the blot for eNOS monomer size a boiled and a non-boiled mouse heart tissue sample was 
run in parallel65. 80 μ g of protein were separated by standard Laemmli conditions with precooled 7.5% gels and 
buffers in an ice bath in the cold room. Proteins were then blotted for 1 h at room temperature to a polyvinylidene 
fluoride (PVDF) membrane, blocked with milk powder in PBS-T (0.1%) for 2 h, and stained for eNOS with 
sc-654 rabbit polyclonal IgG (Santa Cruz Biotechnology, Heidelberg, Germany) and for actin with MAP 1501 R 
(Merck-Millipore, Vienna, Austria). After washing with PBS-T (0.1%), staining with fluorescent secondary anti-
bodies Cy5 anti-rabbit and Cy3 anti-mouse (both from GE Healthcare) membranes were scanned with a three 
colour fluorescence scanner (Typhoon 9410, GE Healthcare) and the intensity of the bands quantified by the 
Imagequant software (GE Healthcare).
Biopterin Measurements by High Performance Liquid Chromatography (HPLC). Intragraft BH4 
concentrations were measured by a method modified from Fukushima and Nixon66. BH4 concentrations were 
calculated as difference of biopterin concentration under acidic and basic oxidation conditions. Dihydrobiopterin 
plus biopterin (BH2 + B) concentrations were calculated as difference between total intragraft biopterin and 
intragraft BH4 concentration.
Statistical Analysis. Results are expressed as mean ± standard error of the mean (SEM). Statistical analysis 
was performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). When comparing multiple 
groups Kruskal-Wallis test was applied. If statistical significance was achieved, all pairs were compared among 
each other using the Mann-Whitney-U and the Bonferroni Multiple Comparison post hoc test. A p value of < 0.05 
was considered to be of statistical significance.
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